IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v9y2018i1d10.1038_s41467-018-07551-w.html
   My bibliography  Save this article

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

Author

Listed:
  • Adriana E. Tron

    (AstraZeneca)

  • Matthew A. Belmonte

    (AstraZeneca
    LifeMine Therapeutics)

  • Ammar Adam

    (AstraZeneca
    Surface Oncology)

  • Brian M. Aquila

    (AstraZeneca
    Alkermes, Inc.)

  • Lawrence H. Boise

    (Emory University School of Medicine
    Winship Cancer Institute of Emory University)

  • Elisabetta Chiarparin

    (AstraZeneca)

  • Justin Cidado

    (AstraZeneca)

  • Kevin J. Embrey

    (AstraZeneca)

  • Eric Gangl

    (AstraZeneca)

  • Francis D. Gibbons

    (AstraZeneca)

  • Gareth P. Gregory

    (Monash University
    Peter MacCallum Cancer Centre)

  • David Hargreaves

    (AstraZeneca)

  • J. Adam Hendricks

    (AstraZeneca)

  • Jeffrey W. Johannes

    (AstraZeneca)

  • Ricky W. Johnstone

    (Peter MacCallum Cancer Centre
    University of Melbourne)

  • Steven L. Kazmirski

    (AstraZeneca
    Fulcrum Therapeutics)

  • Jason G. Kettle

    (AstraZeneca)

  • Michelle L. Lamb

    (AstraZeneca)

  • Shannon M. Matulis

    (Emory University School of Medicine
    Winship Cancer Institute of Emory University)

  • Ajay K. Nooka

    (Emory University School of Medicine
    Winship Cancer Institute of Emory University)

  • Martin J. Packer

    (AstraZeneca)

  • Bo Peng

    (AstraZeneca)

  • Philip B. Rawlins

    (AstraZeneca)

  • Daniel W. Robbins

    (AstraZeneca
    Nurix, Inc.)

  • Alwin G. Schuller

    (AstraZeneca)

  • Nancy Su

    (AstraZeneca)

  • Wenzhan Yang

    (AstraZeneca)

  • Qing Ye

    (AstraZeneca)

  • Xiaolan Zheng

    (AstraZeneca)

  • J. Paul Secrist

    (AstraZeneca
    LifeMine Therapeutics)

  • Edwin A. Clark

    (AstraZeneca)

  • David M. Wilson

    (AstraZeneca)

  • Stephen E. Fawell

    (AstraZeneca)

  • Alexander W. Hird

    (AstraZeneca)

Abstract

Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and resistance to anticancer therapies highlighting the potential of Mcl-1 inhibitors as anticancer drugs. Here, we describe AZD5991, a rationally designed macrocyclic molecule with high selectivity and affinity for Mcl-1 currently in clinical development. Our studies demonstrate that AZD5991 binds directly to Mcl-1 and induces rapid apoptosis in cancer cells, most notably myeloma and acute myeloid leukemia, by activating the Bak-dependent mitochondrial apoptotic pathway. AZD5991 shows potent antitumor activity in vivo with complete tumor regression in several models of multiple myeloma and acute myeloid leukemia after a single tolerated dose as monotherapy or in combination with bortezomib or venetoclax. Based on these promising data, a Phase I clinical trial has been launched for evaluation of AZD5991 in patients with hematological malignancies (NCT03218683).

Suggested Citation

  • Adriana E. Tron & Matthew A. Belmonte & Ammar Adam & Brian M. Aquila & Lawrence H. Boise & Elisabetta Chiarparin & Justin Cidado & Kevin J. Embrey & Eric Gangl & Francis D. Gibbons & Gareth P. Gregory, 2018. "Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia," Nature Communications, Nature, vol. 9(1), pages 1-14, December.
    • Handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-07551-w
    DOI: 10.1038/s41467-018-07551-w
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-018-07551-w
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-018-07551-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Martina Troiani & Manuel Colucci & Mariantonietta D’Ambrosio & Ilaria Guccini & Emiliano Pasquini & Angelica Varesi & Aurora Valdata & Simone Mosole & Ajinkya Revandkar & Giuseppe Attanasio & Andrea R, 2022. "Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    2. Andrea Lopez & Denis E. Reyna & Nadege Gitego & Felix Kopp & Hua Zhou & Miguel A. Miranda-Roman & Lars Ulrik Nordstrøm & Swathi-Rao Narayanagari & Ping Chi & Eduardo Vilar & Aristotelis Tsirigos & Evr, 2022. "Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    3. Juan M. Jiménez-Vacas & Daniel Westaby & Ines Figueiredo & Alexis De Haven Brandon & Ana Padilha & Wei Yuan & George Seed & Denisa Bogdan & Bora Gurel & Claudia Bertan & Susana Miranda & Maryou Lambro, 2025. "Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer," Nature Communications, Nature, vol. 16(1), pages 1-22, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-07551-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.